Literature DB >> 15515031

Dopaminagonists and fibrotic valvular heart disease: further considerations.

Olivier Rascol, Atul Pathak, Haleh Bagheri, J-L Montastruc.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15515031     DOI： 10.1002/mds.20328

Source DB:  PubMed          Journal:  Mov Disord        ISSN： 0885-3185            Impact factor:   10.338


× No keyword cloud information.
  4 in total

Review 1.  Dopamine receptor agonists for the treatment of early or advanced Parkinson's disease.

Authors:  Santiago Perez-Lloret; Olivier Rascol
Journal:  CNS Drugs       Date:  2010-11       Impact factor: 5.749

Review 2.  Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials.

Authors:  Jaime Kulisevsky; Javier Pagonabarraga
Journal:  Drug Saf       Date:  2010-02-01       Impact factor: 5.606

Review 3.  How to optimize the treatment of early stage Parkinson's disease.

Authors:  Fabrizio Stocchi; Laura Vacca; Fabiana G Radicati
Journal:  Transl Neurodegener       Date:  2015-02-25       Impact factor: 8.014

4.  Low incidence of restrictive valvulopathy in patients with Parkinson's disease on moderate dose of pergolide.

Authors:  Evzen Růzicka; Hana Línková; Martin Penicka; Olga Ulmanová; Lucie Nováková; Jan Roth
Journal:  J Neurol       Date:  2007-08-24       Impact factor: 6.682
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.